Lexicon Pharmaceuticals (LXRX) FCF Margin (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 16 years of FCF Margin data on file, last reported at 69.8% in Q1 2026.

• On a quarterly basis, FCF Margin rose 339913.0% year-over-year to 69.8% in Q1 2026; TTM through Mar 2026 was 55.72%, a 48399.0% increase from a year earlier, with the FY2025 full-year figure at 136.24%, up 44229.0% from the prior year.
• FCF Margin for Q1 2026 stood at 69.8%, up from 313.73% in the prior quarter.
• Over the last five years, FCF Margin for LXRX reached as high as 58.87% in Q2 2025 and fell as low as 69777.14% in Q2 2022.
• Historically, FCF Margin has averaged 10030.51% across 5 years, with a median of 3081.49% in 2024.
• Across the five-year window, FCF Margin surged 5663075 bps in 2023 and plunged 23101 bps in 2025, its largest moves.
• Year by year, FCF Margin stood at 69777.14% in 2022, then soared by 91 bps to 6598.96% in 2023, then soared by 99 bps to 82.72% in 2024, then sank by 279 bps to 313.73% in 2025, then soared by 78 bps to 69.8% in 2026.
• Per Business Quant data, the three most recent FCF Margin figures were 69.8% in Q1 2026, 313.73% in Q4 2025, and 168.05% in Q3 2025.